Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

202
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
202
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

182
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
182
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

426
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
426
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

176
In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
176
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

324
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
324
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

231
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
231

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative accuracy of <sup>177</sup>Lu SPECT/CT imaging using ring-shaped CZT versus dual-head NaI systems.

EJNMMI physics·2026
Same author

Oncogenic PIK3CA mutations shape an immunoregulatory microenvironment in mosaic overgrowth disorders.

PNAS nexus·2026
Same author

Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam Radiotherapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

<sup>211</sup>At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.

European journal of nuclear medicine and molecular imaging·2026
Same author

Nephron-Level Dosimetry Reveals Increased Absorbed Dose Heterogeneity of <sup>161</sup>Tb- Versus <sup>177</sup>Lu-DOTATATE in Murine Kidneys Despite Similar Pharmacokinetics.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Monte Carlo calculated beam quality correction factors for light ions used in particle therapy.

Physics in medicine and biology·2026

Related Experiment Video

Updated: Jan 12, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K

A Computational Multinephron Model for Small-Scale Preclinical Renal Dosimetry in Radiopharmaceutical Therapy.

Michelle Andersson1,2, Nicolas Goudin3, Marco Pontoglio4

  • 1Dosimetry Research for Targeted Radionuclide Therapy, Belgian Nuclear Research Centre, Mol, Belgium; michelle.andersson@sckcen.be.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|October 30, 2025
PubMed
Summary

A new multinephron model quantifies kidney radiation dose at the nephron level. This reveals significant dose variations within kidney substructures, crucial for understanding radiopharmaceutical therapy side effects.

Keywords:
MIRDmultinephron mouse kidney modelradiopharmaceutical therapysmall-scale dosimetry

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.7K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K

Related Experiment Videos

Last Updated: Jan 12, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.7K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K

Area of Science:

  • Medical Physics
  • Radiopharmaceutical Therapy
  • Computational Biology

Background:

  • Radiopharmaceutical therapy efficacy is limited by uneven drug distribution in kidneys, causing dose heterogeneity.
  • Accurate absorbed dose-effect relationships for nephrotoxicity are hindered by a lack of substructure-level dosimetry.

Purpose of the Study:

  • To develop a computational model for nephron-level dosimetry in kidney tissues.
  • To quantify absorbed dose heterogeneity within renal substructures using this model.

Main Methods:

  • A multinephron computational model was created using 3D multiphoton microscopy data.
  • Nephron-level S values were calculated via Monte Carlo simulations for various radionuclides.
  • The model was applied to nonuniform uptake data of 225Ac in kidney proximal tubules.

Main Results:

  • Significant absorbed dose heterogeneities were observed across different nephron types and substructures.
  • Juxtamedullary substructures exhibited higher S values compared to superficial ones.
  • Proximal tubules received substantially higher self-doses than glomeruli, with variations based on nephron type and radionuclide.

Conclusions:

  • The developed multinephron framework enables precise nephron-level dosimetry.
  • This model quantifies renal absorbed dose heterogeneity, identifying critical substructures for nephrotoxicity.
  • Findings support the development of nephroprotective strategies for radiopharmaceutical therapy.